Idiopathic Pulmonary Fibrosis

Current Location

31 Idiopathic Pulmonary Fibrosis Trials Near You

Power is an online platform that helps thousands of Idiopathic Pulmonary Fibrosis patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis

Columbus, Ohio
Study RIN-PF-301 is designed to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute forced vital capacity (FVC) from baseline to Week 52.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:40+

576 Participants Needed

BI 1015550 for Pulmonary Fibrosis

Columbus, Ohio
This study is open to people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). They can only take part if they have completed treatment in a previous study with a medicine called nerandomilast or BI 1015550. The goal of this study is to find out how well people with pulmonary fibrosis tolerate long- term treatment with nerandomilast. The study also tests whether nerandomilast improves lung function and prolongs the time until symptoms get worse, participants need to go to the hospital, or die. Every participant takes nerandomilast as tablets for up to 1 year and 10 months. The participants may also continue their regular treatment for pulmonary fibrosis during the study. Participants visit their doctors regularly. During these visits, the doctors collect information on any health problems of the participants. Participants also regularly do lung function tests.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

1700 Participants Needed

Inhaled Treprostinil for Pulmonary Fibrosis

Columbus, Ohio
Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

698 Participants Needed

N-acetyl Cysteine for Idiopathic Pulmonary Fibrosis

Columbus, Ohio
The purpose of this study is to compare the effect of n-acetylcysteine (NAC) plus standard care with matched placebo plus standard of care in patients diagnosed with idiopathic pulmonary fibrosis (IPF) who have the TOLLIP rs3750920 TT genotype. The study will compare the time to a composite endpoint of relative decline in lung function \[10% relative decline in forced vital capacity (FVC), first respiratory hospitalization, lung transplantation, or all-cause mortality\] The secondary objectives will be to examine the effect of NAC on the components of the primary composite endpoint, the rates of clinical events, change in physiology, change in health status, and change in respiratory symptoms.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:40+

202 Participants Needed

BMS-986278 for Pulmonary Fibrosis

Columbus, Ohio
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:21+

1092 Participants Needed

BMS-986278 for Idiopathic Pulmonary Fibrosis

Columbus, Ohio
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:40+

1185 Participants Needed

Inhaled Treprostinil for Pulmonary Fibrosis

Columbus, Ohio
Study RIN-PF-302 is designed to evaluate the long-term safety and tolerability of inhaled treprostinil in subjects with idiopathic pulmonary fibrosis.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Enrolling By Invitation
Trial Phase:Phase 3
Age:40+

792 Participants Needed

AP01 for Pulmonary Fibrosis

Cincinnati, Ohio
A randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of inhaled pirfenidone (AP01) versus placebo on top of standard of care in participants with PPF over 52 weeks.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

300 Participants Needed

Bexotegrast for Idiopathic Pulmonary Fibrosis

Cincinnati, Ohio
This trial is testing a new medication called bexotegrast to see if it can help people with a lung disease called idiopathic pulmonary fibrosis (IPF). The study will include people who are already on other treatments as well as those who are not. The goal is to find out if bexotegrast can improve lung function and slow down the disease.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:40+

360 Participants Needed

LYT-100 (Deupirfenidone) for Idiopathic Pulmonary Fibrosis

Cincinnati, Ohio
This trial tests LYT-100, a new drug, in adults aged 40+ with Idiopathic Pulmonary Fibrosis who haven't been treated before. It aims to see if the drug can slow down the decline in lung function.
Prior Safety Data

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:40+

240 Participants Needed

HZN-825 for Idiopathic Pulmonary Fibrosis

Cleveland, Ohio
This trial tests HZN-825, a new oral medicine, in people with Idiopathic Pulmonary Fibrosis (IPF). The goal is to see if it can help by blocking a receptor that causes lung scarring. The study will check its safety and effectiveness over several months.

Trial Details

Trial Status:Active Not Recruiting

153 Participants Needed

Vixarelimab for Pulmonary Fibrosis

Muncie, Indiana
This trial is testing vixarelimab, a medication that may help improve lung function, in people with IPF and SSc-ILD. It works by reducing inflammation and scarring in the lungs to help with breathing.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

320 Participants Needed

Buloxibutid for Pulmonary Fibrosis

Cleveland, Ohio
The ASPIRE trial is a 52 week randomized, double-blind, placebo-controlled, parallel-group, multicenter trial in which the efficacy, safety, and pharmacokinetics of orally administered buloxibutid, either on top of stable IPF therapy or as monotherapy, are assessed in participants with IPF. Trial website: www.aspire-ipf.com

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:40+

270 Participants Needed

Nalbuphine ER for Pulmonary Fibrosis

Windsor
This is a multi-center randomized, double-blind, placebo-controlled, parallel, 4-arm study of nalbuphine ER (NAL ER). After meeting eligibility during the Screening Period, subjects will be randomized (1:1:1:1) to one of four treatment arms with placebo and increasing doses of nalbuphine ER. Each arm will be titrated to their fixed dose during the blinded 2-week Titration period followed by the 4-week Fixed Dose Period for a total of 6 weeks on drug. For more information see the country specific approved websites: Germany, Netherlands, Poland, Spain, Italy, Chile: TheCoralTrial.com United Kingdom, Australia, Canada: CoralCoughTrial.com Turkey: please refer to the list of locations and reach out to the site directly

Trial Details

Trial Status:Recruiting

160 Participants Needed

ENV-101 for Pulmonary Fibrosis

Ann Arbor, Michigan
The goal of this clinical trial is to evaluate the impact that ENV-101 has on lung function and key measures of fibrosis in adult patients with idiopathic pulmonary fibrosis (IPF). Another goal of this study is to better understand the safety and tolerability of ENV-101 in this patient population.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:40+

200 Participants Needed

GSK3915393 for Pulmonary Fibrosis

Ann Arbor, Michigan
Idiopathic Pulmonary Fibrosis is a chronic lung disease which causes scarring of the lungs and difficulty in breathing. GSK3915393 is a new medicine, which is being tested in participants with IPF for the first time. The study will assess the safety and effectiveness of GSK3915393 in IPF participants.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

150 Participants Needed

Lung and Bone Marrow Transplant for Pulmonary Fibrosis

Pittsburgh, Pennsylvania
The purpose of this study is to determine whether a lung transplantation prior to bone marrow transplantation (BMT) would allow for restoration of pulmonary function prior to BMT, allowing to proceed to BMT, to restore hematologic function.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18 - 60

8 Participants Needed

DWN12088 for Idiopathic Pulmonary Fibrosis

Pittsburgh, Pennsylvania
This trial is testing a new drug called DWN12088 to see if it can help people with Idiopathic Pulmonary Fibrosis, a serious lung disease. The study will check if the drug is safe and effective. The exact way the drug works is not detailed, but it aims to improve lung function or slow down the disease.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:40+

102 Participants Needed

EGCG for Pulmonary Fibrosis

Ann Arbor, Michigan
This trial is testing EGCG, a compound from green tea, in patients with idiopathic pulmonary fibrosis (IPF). The goal is to see if EGCG can safely reduce lung scarring. EGCG works by blocking harmful signals that cause lung tissue to harden. Epigallocatechin-3-gallate (EGCG) is a polyphenol and a major component of green tea, known for its potent antioxidant, anti-inflammatory, and anti-fibrotic properties.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Age:40 - 85

50 Participants Needed

EGCG for Pulmonary Fibrosis

Ann Arbor, Michigan
The primary purpose of this substudy is to determine if collagen-targeted PET using the type 1 collagen-targeted PET probe, Gallium-68 (68Ga)-labeled collagen binding probe 8 (CBP8) can inform as to drug effect of EGCG and assist in dose selection.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Age:40 - 85

22 Participants Needed

Why Other Patients Applied

"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

IZ
Healthy Volunteer PatientAge: 38

"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

WR
Obesity PatientAge: 58

"I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

ZS
Depression PatientAge: 51

"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

HZ
Arthritis PatientAge: 78

"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

ID
Pancreatic Cancer PatientAge: 40

Ifetroban for Pulmonary Fibrosis

Indianapolis, Indiana
Ifetroban prevents and treats lung fibrosis due to multiple causes (bleomycin, genetic, radiation). The safety and efficacy of oral ifetroban will be assessed in patients with IPF.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:40 - 80

128 Participants Needed

BI 1819479 for Pulmonary Fibrosis

Warren, Michigan
This study is open to adults 40 years or older with idiopathic pulmonary fibrosis (IPF). People can join the study if they are not on any treatment for IPF are on stable treatment for at least 3 months before starting the study. The purpose of this study is to find out whether a medicine called BI 1819479 helps people with IPF. 3 different doses of BI 1819479 are tested in this study. Participants are put into 4 groups by chance. Participants in 3 groups get different doses of BI 1819479. Participants in 1 group get placebo. Placebo tablets look like BI 1819479 tablets, but do not contain any medicine. Participants take the treatment for 6 months to 1 year. Participants are in the study for up to 1 year and 2 months. During this time, they visit the study site between 10 and 12 times and get up to 11 phone calls from the site staff. At site visits doctors regularly perform breathing tests that measure how well the lungs are working. Researchers compare the results between participants who take BI 1819479 and placebo. The doctors also regularly check participants' health and take note of any unwanted effects.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:40+

319 Participants Needed

BI 1839100 for Pulmonary Fibrosis

Warren, Michigan
Adults 40 years of age and older with idiopathic pulmonary fibrosis (IPF) or 18 years and older with progressive pulmonary fibrosis (PPF) can participate in this study. Only people who have a chronic cough can take part. The purpose of this study is to find out how well BI 1839100 helps reduce coughing in people with IPF or PPF. Participants who have IPF are put into 4 groups by chance. Participants in 3 groups get different doses of BI 1839100. Participants in 1 group get placebo. Placebo looks like BI 1839100 but does not contain any medicine. Participants take the treatment for 3 months. After 1 month of treatment, participants who take the highest dose will have coughing measured to find out if the medicine works. If it does not work, the study may be stopped. Participants who have IPF are in the study for slightly longer than 4 months. During this time, they visit the study site 7 times. This study will also measure the effects of BI 1839100 on coughing and lung function in a smaller group of people with PPF. During the study, coughing is measured over 24 hours about once per month using a portable device given to participants to use during the study. Participants fill in questionnaires about their coughing. Doctors also perform breathing tests that measure how well the lungs are working at the site visits. Researchers compare the results between participants who take BI 1839100 and placebo. The doctors also regularly check participants' health and take note of any unwanted effects.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

230 Participants Needed

TTI-101 for Idiopathic Pulmonary Fibrosis

Chicago, Illinois
The primary objective of this study is to evaluate the safety and tolerability of oral daily administration of TTI-101 over a 12-week treatment duration in participants with idiopathic pulmonary fibrosis (IPF).

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:40+

75 Participants Needed

Hyperpolarized Xenon-129 MRI for Idiopathic Pulmonary Fibrosis

Charlottesville, Virginia
Idiopathic pulmonary fibrosis has a poor prognosis with limited treatment options. The Investigator hypothesize hyperpolarized Xe129-MRI can be performed in patients with IPF and repeated over time which will detect deficiencies related to perfusion in the lung.
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Early Phase 1

6 Participants Needed

High Oxygen Delivery for Idiopathic Pulmonary Fibrosis

Hamilton, Ontario
The purpose is to determine if patients with idiopathic pulmonary fibrosis (IPF) taking nintedanib will have improved exercise endurance, breathlessness and quality of life if breathing 60% oxygen compared to standard of care during an 8 week exercise training program.

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:19+

88 Participants Needed

BBT-877 for Idiopathic Pulmonary Fibrosis

Chicago, Illinois
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, study to evaluate the efficacy, safety, and tolerability of 200 mg twice daily (BID) of BBT-877 in patients with IPF, with or without AF approved background therapies (pirfenidone or nintedanib).

Trial Details

Trial Status:Active Not Recruiting
Age:40+

129 Participants Needed

GRI-0621 for Pulmonary Fibrosis

Winston Salem, North Carolina
This is a Phase 2a, randomized, double-blind, multi-center, placebo-controlled, parallel-design, 2-arm study. Approximately 36 subjects with IPF will be randomized in a 2:1 ratio for GRI-0621 4.5mg or Placebo. GRI-0621 dose of 4.5mg will be compared with placebo following once daily oral administration for 12 weeks. Concurrently, a Sub-Study will be conducted, examining the number and activity of NKT cells in BAL, for up to 12 eligible subjects (across various centers). An early-stage patient variability assessment will be completed when 12 subjects have completed 2 weeks of treatment. Followed by an interim analysis performed when 24 subjects complete 6 weeks of treatment.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:40 - 85

36 Participants Needed

INS018_055 for Idiopathic Pulmonary Fibrosis

Winston-Salem, North Carolina
This trial tests a new oral medication, INS018_055, in adults with Idiopathic Pulmonary Fibrosis (IPF). It aims to see if the medication is safe and well-tolerated over a few months.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:40+

60 Participants Needed

One-Legged vs Two-Legged Cycle Training for Idiopathic Pulmonary Fibrosis

Toronto, Ontario
Idiopathic pulmonary fibrosis (IPF) is a lung disease that limits the ability to breathe enough for a good workout. One way to improve the exercise training is to reduce the number of muscles being trained together. By training one leg at a time, the patient does not have to breathe as much allowing each leg a better workout. Our groundwork suggests it may work in patients with IPF. This study will help decide whether one-legged exercise training is better at improving a patient's exercise endurance compared to the usual way of exercising with both legs at the same time.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

50 Participants Needed

12

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

Frequently Asked Questions

How much do Idiopathic Pulmonary Fibrosis clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Idiopathic Pulmonary Fibrosis clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Idiopathic Pulmonary Fibrosis trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Idiopathic Pulmonary Fibrosis is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Idiopathic Pulmonary Fibrosis medical study?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Idiopathic Pulmonary Fibrosis clinical trials?

Most recently, we added Hymecromone for Interstitial Lung Disease, Hyperpolarized Xenon-129 MRI for Idiopathic Pulmonary Fibrosis and Buloxibutid for Pulmonary Fibrosis to the Power online platform.

Popular Searches

By Condition

Depression Clinical Trials

Anxiety Clinical Trials

Schizophrenia Clinical Trials

ADHD Clinical Trials

Bipolar Disorder Clinical Trials

Multiple Sclerosis Clinical Trials

Autism Clinical Trials

Treatment Resistant Depression Clinical Trials

Borderline Personality Disorder Clinical Trials

Social Anxiety Disorder Clinical Trials

Parkinson's Disease Clinical Trials

Alzheimer's Disease Clinical Trials

By Location

Clinical Trials in California

Clinical Trials in Florida

Clinical Trials in Texas

Clinical Trials in New York

Clinical Trials in Ohio

Clinical Trials in Illinois

Clinical Trials in Pennsylvania

Clinical Trials in Michigan

Clinical Trials in North Carolina

Clinical Trials in Massachusetts

Clinical Trials in Missouri

Clinical Trials in Minnesota

Other People Viewed

By Subject

Top Pulmonary Fibrosis Clinical Trials

Top Idiopathic Intracranial Hypertension Clinical Trials

Top Juvenile Idiopathic Arthritis Clinical Trials

Top Fibrosis Clinical Trials

Top Liver Fibrosis Clinical Trials

Top Cystic Fibrosis Clinical Trials

Top Pulmonary Hypertension Clinical Trials

Top Pulmonary Embolism Clinical Trials

Top Chronic Obstructive Pulmonary Disease Clinical Trials

Top Idiopathic Hypersomnia Clinical Trials

Top Pulmonary Arterial Hypertension Clinical Trials

Top Adenovirus Clinical Trials

By Trial

PET/CT Imaging for Idiopathic Pulmonary Fibrosis

Inhaled Treprostinil for Pulmonary Fibrosis

N-acetyl Cysteine for Idiopathic Pulmonary Fibrosis

LTI-03 for Pulmonary Fibrosis

VX-522 mRNA Therapy for Cystic Fibrosis

Ferumoxytol for Infant Pulmonary Vein Stenosis

Dopamine for Pulmonary Diffusion and Capillary Blood Volume during Exercise. However, since the Layman Condition List is "Health" which is very broad, it is difficult to specify a specific condition for this trial

MID-C System for Adolescent Idiopathic Scoliosis

Anticoagulation vs Thrombectomy for Pulmonary Embolism

Trikafta for Bronchiectasis

Vosoritide for Idiopathic Short Stature

Symphony Thrombectomy for Pulmonary Embolism

Related Searches

Top Autism Clinical Trials near Long Beach, CA

Drug-Releasing Cochlear Implant for Hearing Loss

Plozasiran for High Triglycerides

Methadone for Pain Management in Spinal Surgery

TAK-279 for Crohn's Disease

Chemotherapy + Radiation Therapy for Head and Neck Cancer

Pelacarsen for Cardiovascular Disease

Endoscopic Sleeve Gastroplasty Techniques for Obesity

Peanut Meal for Healthy Aging

App-Based Program for Anxiety and Depression

Viral-Specific T-cell Therapy for Post-Transplant Viral Infections

READY4Life Programming for Life Skills

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security
Match to a Trial